How we grade
6 rules
An entry does not start with a grade. It starts with a source, and everything after that is the work of checking whether that source holds up: whether the study itself was peer reviewed — checked by other scientists before it was published — and whether every number in it traces back to something a reader could open themselves.
What follows is that process in full: the rules every entry has to survive before it is published, from which sources we accept to what we do when we get something wrong.
The five levels themselves, and how many peptides in the register sit on each one, are covered on The evidence scale.
The rules we follow
Which sources count
We cite original sources wherever we can: published studies with a DOI, the official product information from the European and US regulators, decisions from the Swedish Medical Products Agency, the text of the law itself, and the World Anti-Doping Agency's prohibited list. We use summaries and review articles only when they are summarising that kind of material.
We never cite a shop, a forum, a podcast, or an article that has no source of its own. If a claim can only be traced back to someone who makes money from the compound, we do not publish the claim.
How we check the chain
Every amino acid sequence is looked up in the public chemical and protein databases and compared letter by letter. If we cannot confirm it there, we print no sequence at all — the field says so plainly instead.
Leaving the gap visible is deliberate. A wrong sequence is worse than an empty box, because it looks exactly as trustworthy as a correct one.
How each entry gets checked
Every claim in the register names the source it came from, right next to it — a study, a regulator's own page, the text of a law. Open the citation and check it yourself.
When there is doubt, the level always goes down, never up. An open-label study in twelve people is limited human data, not a late-stage trial.
What we deliberately leave out
No doses. No instructions for taking anything. No suppliers, shops or price comparisons. That applies to approved medicines too — that conversation belongs with a doctor, not on a web page.
Advertising an unapproved medicine to the public is also illegal in Sweden under the Medicinal Products Act (2015:315). Describing what the evidence shows is not advertising. Describing how to use these compounds would be.
How we write about what we don't know
Where the evidence is missing, we say it is missing, as plainly as we would report a positive result. We only write "studies suggest" when there are studies, and then we name them.
The register has no opinion about whether something is good. It only has a view on how much is actually known.
Mistakes and updates
We review entries again when new evidence is published, when an approval changes, or when the doping list is updated. The date at the top of the page is when we last went through it, not when we last edited a word.
If you find a mistake, we want to know. Send the source along with the claim you think is wrong, and we will correct it and note the change.
Peptide Reader does not tell you what to do. It tells you what is known, and how well.
Peptide Reader is a reference work, not medical advice. Where an amount appears it is what a named study gave its participants, reported as a fact about that study. The site carries no instructions for use and no places to buy. Always talk to a doctor about treatment.
Browse peptides